[{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Sustained-Release Implant","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Not Applicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mediprint Ophthalmics \/ Not Applicable"},{"orgOrder":0,"company":"Famar Health Care Services Madrid","sponsor":"Medicom Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Famar Health Care Services Madrid","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Famar Health Care Services Madrid \/ Medicom Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Famar Health Care Services Madrid \/ Medicom Healthcare"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Allergan Aesthetics \/ Abbvie","highestDevelopmentStatusID":"12","companyTruncated":"Allergan Aesthetics \/ Abbvie"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"sGC","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Not Applicable"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Allergan Aesthetics \/ Not Applicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"sGC Inhibitor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Not Applicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"PGF2 alpha receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Not Applicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Private Placement","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Medicom Healthcare","sponsor":"Famar","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Medicom Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Medicom Healthcare \/ Famar","highestDevelopmentStatusID":"12","companyTruncated":"Medicom Healthcare \/ Famar"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aequus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"SpyGlass Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Mr. Doug Janzen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Mr. Doug Janzen","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pharmaceuticals \/ Mr. Doug Janzen"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Implant","sponsorNew":"SpyGlass Pharma \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ RA Capital Management"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Kowa Company","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Kowa Company"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Not Applicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"SpyGlass Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpyGlass Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/ Not Applicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Aequus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Mediprint Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mediprint Ophthalmics \/ Not Applicable"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Laboratoires Thea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Laboratoires Thea \/ Not Applicable"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nicox SA \/ Not Applicable"},{"orgOrder":0,"company":"Viwit Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Viwit Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Viwit Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viwit Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"SpyGlass Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Technology","graph2":"Approved","graph3":"SpyGlass Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"SpyGlass Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SpyGlass Pharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Bimatoprost
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
